The global skeletal dysplasia market size accounted for $1,638.10 million in 2021, and is expected to reach $2,360.51 million by 2031, registering a CAGR of 3.7% from 2022 to 2031.
Skeletal dysplasia is a rare disease that has more than 450 types. The growth and development of cartilage and bone get affected by this disease. The level of severity of the disease varies from neutral lethality to growth different in adulthood. Skeletal dysplasia is complex to diagnosis, as it is rare disorder. Some of the major symptoms are deformities in the large head, slow growth, curved bones, short upper arms and thighs and joint pain or arthritis.
This disorder is prevalent in children and early treatment can help to create awareness. This disorder is result of defective genes, which are either mutated during the development of fetus or inherited from parents. The defense gene is most complex to identify. As a result, businesses are investing significantly in research and development to find a cure for this rare condition. It is estimated that skeletal dysplasia market is expected to experience significant market growth during the forecast period owing to the increasing pediatric population suffering from bone disorder, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure which further facilitate the growth of the market. However, High cost of treatment is expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the skeletal dysplasia market.
The skeletal dysplasia market is segmented on the basis of type, treatment, distribution channel and region. On the basis of type, the market is bifurcated into morquio A syndrome, X-linked hypophosphatemia, hypophosphatasia and others. Depending on treatment, the market is classified into enzyme replacement therapy, human monoclonal antibody and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and specialty pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides -A comprehensive analysis of the key players that operate in the global skeletal dysplasia market. The key companies profiled in the report include Amgen Inc., Ascendis Pharma a/s, AstraZeneca plc., Biomarin Pharmaceuticals Inc., Cipla Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Skeletal dysplasia is a rare disease that has more than 450 types. The growth and development of cartilage and bone get affected by this disease. The level of severity of the disease varies from neutral lethality to growth different in adulthood. Skeletal dysplasia is complex to diagnosis, as it is rare disorder. Some of the major symptoms are deformities in the large head, slow growth, curved bones, short upper arms and thighs and joint pain or arthritis.
This disorder is prevalent in children and early treatment can help to create awareness. This disorder is result of defective genes, which are either mutated during the development of fetus or inherited from parents. The defense gene is most complex to identify. As a result, businesses are investing significantly in research and development to find a cure for this rare condition. It is estimated that skeletal dysplasia market is expected to experience significant market growth during the forecast period owing to the increasing pediatric population suffering from bone disorder, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure which further facilitate the growth of the market. However, High cost of treatment is expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the skeletal dysplasia market.
The skeletal dysplasia market is segmented on the basis of type, treatment, distribution channel and region. On the basis of type, the market is bifurcated into morquio A syndrome, X-linked hypophosphatemia, hypophosphatasia and others. Depending on treatment, the market is classified into enzyme replacement therapy, human monoclonal antibody and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and specialty pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides -A comprehensive analysis of the key players that operate in the global skeletal dysplasia market. The key companies profiled in the report include Amgen Inc., Ascendis Pharma a/s, AstraZeneca plc., Biomarin Pharmaceuticals Inc., Cipla Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skeletal dysplasia market analysis from 2021 to 2031 to identify the prevailing skeletal dysplasia market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the skeletal dysplasia market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global skeletal dysplasia market trends, key players, market segments, application areas, and market growth Strategies.
Key Market Segments
By Type
- Morquio A syndrome
- X-linked hypophosphatemia
- Hypophosphatasia
By Treatment
- Enzyme replacement therapy
- Human monoclonal antibody
By Distribution Channel
- Hospital pharmacies
- Drug store and specialty pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
Key Market Players
- Amgen Inc.
- AstraZeneca plc
- Cipla Ltd
- Merck KGaA
- Ascendis pharma a/s
- F. Hoffmann-La Roche AG
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Biomarin Pharmaceuticals Inc.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. Moderate threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of skeletal dysplasia
3.4.1.2. Commercialization of novel drugs and presence of pipeline products
3.4.1.3. Increase in government expenditure on healthcare
3.4.1.4. Increase in the number of clinical trials and collaborative research for skeletal dysplasia treatment
3.4.2. Restraints
3.4.2.1. Strict regulatory rules and high cost
3.4.3. Opportunities
3.4.3.1. Growth opportunities in the emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: SKELETAL DYSPLASIA MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Morquio A syndrome
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. X-linked hypophosphatemia
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Hypophosphatasia
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: SKELETAL DYSPLASIA MARKET, BY TREATMENT
5.1. Overview
5.1.1. Market size and forecast
5.2. Enzyme replacement therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Human monoclonal antibody
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug store and specialty pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: SKELETAL DYSPLASIA MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Treatment
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Treatment
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Treatment
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Treatment
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Treatment
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Treatment
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Treatment
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Treatment
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Treatment
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Treatment
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Treatment
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Treatment
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Treatment
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Treatment
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Treatment
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Treatment
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Treatment
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Treatment
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Treatment
7.5.5.2.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Amgen Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. AstraZeneca plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Eli Lilly and Company
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Cipla Ltd
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Biomarin Pharmaceuticals Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Teva Pharmaceutical Industries Ltd.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Merck KGaA
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Ascendis pharma a/s
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Pfizer, Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. F. Hoffmann-La Roche AG
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
List of Tables
Table 01. Global Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 02. Skeletal Dysplasia Market for Morquio a Syndrome, by Region, 2021-2031 (Revenue, $Million)
Table 03. Skeletal Dysplasia Market for X-Linked Hypophosphatemia, by Region, 2021-2031 (Revenue, $Million)
Table 04. Skeletal Dysplasia Market for Hypophosphatasia, by Region, 2021-2031 (Revenue, $Million)
Table 05. Skeletal Dysplasia Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 06. Global Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 07. Skeletal Dysplasia Market for Enzyme Replacement Therapy, by Region, 2021-2031 (Revenue, $Million)
Table 08. Skeletal Dysplasia Market for Human Monoclonal Antibody, by Region, 2021-2031 (Revenue, $Million)
Table 09. Skeletal Dysplasia Market for Others, by Region, 2021-2031 (Revenue, $Million)
Table 10. Global Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 11. Skeletal Dysplasia Market for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 12. Skeletal Dysplasia Market for Drug Store and Specialty Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 13. Skeletal Dysplasia Market for Online Providers, by Region, 2021-2031 (Revenue, $Million)
Table 14. Skeletal Dysplasia Market, by Region, 2021-2031 (Revenue, $Million)
Table 15. North America Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 16. North America Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 17. North America Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 18. North America Skeletal Dysplasia Market, by Country, 2021-2031 (Revenue, $Million)
Table 19. U.S. Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 20. U.S. Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 21. U.S. Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 22. Canada Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 23. Canada Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 24. Canada Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 25. Mexico Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 26. Mexico Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 27. Mexico Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 28. Europe Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 29. Europe Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 30. Europe Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 31. Europe Skeletal Dysplasia Market, by Country, 2021-2031 (Revenue, $Million)
Table 32. Germany Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 33. Germany Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 34. Germany Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 35. France Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 36. France Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 37. France Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 38. UK Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 39. UK Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 40. UK Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 41. Italy Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 42. Italy Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 43. Italy Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 44. Spain Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 45. Spain Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 46. Spain Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 47. Rest of Europe Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 48. Rest of Europe Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 49. Rest of Europe Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 50. Asia-Pacific Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 51. Asia-Pacific Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 52. Asia-Pacific Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 53. Asia-Pacific Skeletal Dysplasia Market, by Country, 2021-2031 (Revenue, $Million)
Table 54. Japan Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 55. Japan Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 56. Japan Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 57. China Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 58. China Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 59. China Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 60. India Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 61. India Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 62. India Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 63. Rest of Asia-Pacific Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 64. Rest of Asia-Pacific Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 65. Rest of Asia-Pacific Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 66. LAMEA Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 67. LAMEA Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 68. LAMEA Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 69. LAMEA Skeletal Dysplasia Market, by Country, 2021-2031 (Revenue, $Million)
Table 70. Latin America Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 71. Latin America Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 72. Latin America Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 73. Middle East and Africa Skeletal Dysplasia Market, by Type, 2021-2031 (Revenue, $Million)
Table 74. Middle East and Africa Skeletal Dysplasia Market, by Treatment, 2021-2031 (Revenue, $Million)
Table 75. Middle East and Africa Skeletal Dysplasia Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 76. Amgen Inc.: Key Executives
Table 77. Amgen Inc.: Company Snapshot
Table 78. Amgen Inc.: Product Segments
Table 79. Amgen Inc.: Product Portfolio
Table 80. Astrazeneca PLC: Key Executives
Table 81. Astrazeneca PLC: Company Snapshot
Table 82. Astrazeneca PLC: Product Segments
Table 83. Astrazeneca PLC: Product Portfolio
Table 84. Eli Lilly and Company: Key Executives
Table 85. Eli Lilly and Company: Company Snapshot
Table 86. Eli Lilly and Company: Product Segments
Table 87. Eli Lilly and Company: Product Portfolio
Table 88. Cipla Ltd.: Key Executives
Table 89. Cipla Ltd.: Company Snapshot
Table 90. Cipla Ltd.: Product Segments
Table 91. Cipla Ltd.: Product Portfolio
Table 92. Biomarin Pharmaceuticals Inc.: Key Executives
Table 93. Biomarin Pharmaceuticals Inc.: Company Snapshot
Table 94. Biomarin Pharmaceuticals Inc.: Product Segments
Table 95. Biomarin Pharmaceuticals Inc.: Product Portfolio
Table 96. Biomarin Pharmaceuticals Inc.: Key Strategies
Table 97. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 98. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 99. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 100. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 101. Merck KGaA: Key Executives
Table 102. Merck KGaA: Company Snapshot
Table 103. Merck KGaA: Product Segments
Table 104. Merck KGaA: Product Portfolio
Table 105. Ascendis Pharma A/S: Key Executives
Table 106. Ascendis Pharma A/S: Company Snapshot
Table 107. Ascendis Pharma A/S: Product Segments
Table 108. Ascendis Pharma A/S: Product Portfolio
Table 109. Ascendis Pharma A/S: Key Strategies
Table 110. Pfizer, Inc.: Key Executives
Table 111. Pfizer, Inc.: Company Snapshot
Table 112. Pfizer, Inc.: Product Segments
Table 113. Pfizer, Inc.: Product Portfolio
Table 114. Pfizer, Inc.: Key Strategies
Table 115. F. Hoffmann-La Roche AG: Key Executives
Table 116. F. Hoffmann-La Roche AG: Company Snapshot
Table 117. F. Hoffmann-La Roche AG: Product Segments
Table 118. F. Hoffmann-La Roche AG: Product Portfolio
List of Figures
Figure 01. Skeletal Dysplasia Market, 2021-2031
Figure 02. Segmentation of Skeletal Dysplasia Market, 2021-2031
Figure 03. Top Investment Pockets in Skeletal Dysplasia Market (2022-2031)
Figure 04. High Bargaining Power of Suppliers
Figure 05. Moderate Bargaining Power of Buyers
Figure 06. Moderate Threat of Substitutes
Figure 07. Moderate Threat of New Entrants
Figure 08. Moderate Intensity of Rivalry
Figure 09. Drivers, Restraints and Opportunities: Globalskeletal Dysplasia Market
Figure 10. Skeletal Dysplasia Market, by Type, 2021(%)
Figure 11. Comparative Share Analysis of Skeletal Dysplasia Market for Morquio a Syndrome, by Country 2021-2031(%)
Figure 12. Comparative Share Analysis of Skeletal Dysplasia Market for X-Linked Hypophosphatemia, by Country 2021-2031(%)
Figure 13. Comparative Share Analysis of Skeletal Dysplasia Market for Hypophosphatasia, by Country 2021-2031(%)
Figure 14. Comparative Share Analysis of Skeletal Dysplasia Market for Others, by Country 2021-2031(%)
Figure 15. Skeletal Dysplasia Market, by Treatment, 2021(%)
Figure 16. Comparative Share Analysis of Skeletal Dysplasia Market for Enzyme Replacement Therapy, by Country 2021-2031(%)
Figure 17. Comparative Share Analysis of Skeletal Dysplasia Market for Human Monoclonal Antibody, by Country 2021-2031(%)
Figure 18. Comparative Share Analysis of Skeletal Dysplasia Market for Others, by Country 2021-2031(%)
Figure 19. Skeletal Dysplasia Market, by Distribution Channel, 2021(%)
Figure 20. Comparative Share Analysis of Skeletal Dysplasia Market for Hospital Pharmacies, by Country 2021-2031(%)
Figure 21. Comparative Share Analysis of Skeletal Dysplasia Market for Drug Store and Specialty Pharmacies, by Country 2021-2031(%)
Figure 22. Comparative Share Analysis of Skeletal Dysplasia Market for Online Providers, by Country 2021-2031(%)
Figure 23. Skeletal Dysplasia Market by Region, 2021
Figure 24. U.S. Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 25. Canada Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 26. Mexico Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 27. Germany Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 28. France Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 29. UK Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 30. Italy Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 31. Spain Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 32. Rest of Europe Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 33. Japan Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 34. China Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 35. India Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 36. Rest of Asia-Pacific Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 37. Latin America Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 38. Middle East and Africa Skeletal Dysplasia Market, 2021-2031 ($Million)
Figure 39. Top Winning Strategies, by Year
Figure 40. Top Winning Strategies, by Development
Figure 41. Top Winning Strategies, by Company
Figure 42. Product Mapping of Top 10 Players
Figure 43. Competitive Dashboard
Figure 44. Competitive Heatmap: Skeletal Dysplasia Market
Figure 45. Top Player Positioning, 2021
Figure 46. Amgen Inc.: Net Revenue, 2019-2021 ($Million)
Figure 47. Amgen Inc.: Revenue Share by Region, 2021 (%)
Figure 48. Astrazeneca PLC: Net Revenue, 2019-2021 ($Million)
Figure 49. Astrazeneca PLC: Revenue Share by Segment, 2021 (%)
Figure 50. Astrazeneca PLC: Revenue Share by Region, 2021 (%)
Figure 51. Eli Lilly and Company: Net Revenue, 2019-2021 ($Million)
Figure 52. Eli Lilly and Company: Revenue Share by Region, 2021 (%)
Figure 53. Biomarin Pharmaceuticals Inc.: Net Revenue, 2019-2021 ($Million)
Figure 54. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2021 ($Million)
Figure 55. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2021 (%)
Figure 56. Merck KGaA: Net Sales, 2019-2021 ($Million)
Figure 57. Merck KGaA: Revenue Share by Segment, 2021 (%)
Figure 58. Merck KGaA: Revenue Share by Region, 2021 (%)
Figure 59. Ascendis Pharma A/S: Net Revenue, 2019-2021 ($Million)
Figure 60. Ascendis Pharma A/S: Revenue Share by Region, 2021 (%)
Figure 61. Pfizer, Inc.: Net Revenue, 2019-2021 ($Million)
Figure 62. Pfizer, Inc.: Revenue Share by Region, 2021 (%)
Figure 63. F. Hoffmann-La Roche AG: Net Revenue, 2019-2021 ($Million)
Figure 64. F. Hoffmann-La Roche AG: Revenue Share by Segment, 2021 (%)
Executive Summary
According to the report titled, 'Skeletal Dysplasia Market,' the skeletal dysplasia market size was valued at $1,638.1 million in 2021, and is estimated to reach $2,360.51 million by 2031, growing at a CAGR of 3.7% from 2022 to 2031.Skeletal dysplasia includes a broad spectrum of diseases that affect bones and cartilage development. Due to the extraordinarily wide range, any component of the skeleton, including problems in bone size, shape, density, and short stature, may be impacted. Skeletal dysplasia is brought on by a disturbance of fetal bone development. Skeletal dysplasia can be found in some cases before birth and in others after. It is linked to problems with the joints, the nervous system, the lungs, the eyes, the ears, the heart, and the kidneys.
Key factors driving the growth of the skeletal dysplasia market include an increase in congenital diseases instances and a surge in the demand for treatments used to treat different types of skeletal dysplasia. Furthermore, there are government-funded initiatives to correct birth abnormalities as well as a favourable reimbursement environment. During the projected period, this aspect will further fuel market growth. Rise in prevalence of skeletal dysplasia such as achondroplasia, osteogenesis imperfecta, thanatophoric dysplasia and others drive the growth of the market. For instance, according to National Library of Medicine Every year, Thanatophoric dysplasia (TD) occurs in 1 in 20,000 to 50,000 newborns worldwide. Type I thanatophoric dysplasia is more common than type II.
Furthermore, In June 2020, according to National Organization for Rare Disorders, osteogenesis imperfecta (OI) type I is estimated to occur in one in 30,000 live births. OI type II is estimated to occur in one in 60,000 live births. The overall prevalence of all types of osteogeneses imperfecta is estimated at 5 per 10,000 individuals in the U.S. Approximately 20,000 to 50,000 individuals in the U.S. have osteogenesis imperfecta. Moreover, as per the data published by the European Medicines Agency in June 2021, it is projected that 350 children are born with achondroplasia each year in Europe. Thus, increase in prevalence of skeletal dysplasia is expected to drive the growth of the market.
The market also offers growth opportunities to the key players in the market. Novel drugs commercialization and the presence of pipeline products are the key reasons for the growth of the market. Key players in the market are engaged in research and development to provide advanced medications and novel treatments for skeletal dysplasia. During the projected period, it is anticipated that the strategic collaborative research and medication designation approvals in the industry would considerably fuel market expansion and generate development potential during the forecast period
For instance, in October 2019, Recombinetics and Mayo Clinic collaborated on a research project. The development of the first osteogenesis imperfecta swine models was the main objective of this collaboration, which aimed to enhance osteogenesis imperfecta research. These models will help preclinical researchers to understand the etiology and progression of the disease, providing a reliable preclinical model to determine the safety and effectiveness of novel medicines required for patients suffering osteogenesis imperfecta. Therefore, the aforementioned factors boost the growth of the market.
The skeletal dysplasia market is segmented on the basis of type, treatment, distribution channel and region. On the basis of type, the market is bifurcated into morquio A syndrome, X-linked hypophosphatemia, hypophosphatasia and others. Depending on treatment, the market is classified into enzyme replacement therapy, human monoclonal antibody and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and specialty pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global skeletal dysplasia market. The key companies profiled in the report include Amgen Inc., Ascendis Pharma a/s, AstraZeneca plc., Biomarin Pharmaceuticals Inc., Cipla Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. The players in the market have been actively engaged in the adoption various Strategies such as acquisition, and product approval. For instance, Denosumab is a phase III clinical trial medication being developed by Amgen Inc. for the treatment of Osteogenesis Imperfecta (OI).
Key Market Insights
On the basis of type, the morquio A syndrome segment dominated the market in 2021, and is expected to continue this trend during the forecast period.On the basis of treatment, the enzyme treatment therapy segment is dominated the market in 2021, and is expected to continue this trend during the forecast period.
Depending on distribution channel, drug stores and specialty pharmacies segment are projected to grow at CAGR of 3.9% during the forecast period.
Region-wise, North-America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Amgen Inc.
- AstraZeneca plc
- Cipla Ltd
- Merck KGaA
- Ascendis pharma a/s
- F. Hoffmann-La Roche AG
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Biomarin Pharmaceuticals Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 355 |
| Published | January 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1638.1 million |
| Forecasted Market Value ( USD | $ 2360.51 million |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
